ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
GH Research PLC

GH Research PLC (GHRS)

9,10
-0,01
(-0,11%)
Geschlossen 27 November 10:00PM
9,01
-0,09
(-0,99%)
Nach Börsenschluss: 1:59AM

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Current Price
9,10
Gebot
8,50
Fragen
12,00
Volumen
38.680
8,66 Tagesbereich 9,45
5,05 52-Wochen-Bereich 14,99
Marktkapitalisierung
Handelsende
9,11
Handelsbeginn
9,17
Letzte Trade
20
@
9.11
Letzter Handelszeitpunkt
Finanzvolumen
US$ 352.228
VWAP
9,1062
Durchschnittliches Volumen (3 Mio.)
60.129
Ausgegebene Aktien
52.028.145
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-13,17
Gewinn pro Aktie (EPS)
-0,68
Erlöse
-
Nettogewinn
-35,59M

Über GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
Hauptsitz
Dublin, Irl
Gegründet
-
GH Research PLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GHRS. The last closing price for GH Research was US$9,11. Over the last year, GH Research shares have traded in a share price range of US$ 5,05 to US$ 14,99.

GH Research currently has 52.028.145 shares in issue. The market capitalisation of GH Research is US$473,98 million. GH Research has a price to earnings ratio (PE ratio) of -13.17.

GHRS Neueste Nachrichten

GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024Phase 1 clinical trial to evaluate proprietary aerosol...

GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and expected completion of 6-month open-label...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.38-4.008438818579.4811.099.01628019.79063706CS
41.0412.90322580658.0611.097.7342724259.02536387CS
12-0.99-9.8116947472710.0911.096601298.05701652CS
26-4.9-351414.996510709.72709975CS
522.1330.55954088956.9714.995.05783808.93117389CS
156-16.01-63.759458383125.1127.785.057926712.07441837CS
260-12.9-58.63636363642230.435.058157813.45477838CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
PSTXPoseida Therapeutics Inc
US$ 9,38
(227,97%)
30,14M
IMGCIMG Inc
US$ 1,615
(156,35%)
114,51M
IDAIT Stamp Inc
US$ 0,364
(102,22%)
560,18M
PGHLPrimega Group Holdings Ltd
US$ 20,95
(98,77%)
2,89M
TOYOTOYO Company Ltd
US$ 5,41
(86,55%)
49,09M
ALECAlector Inc
US$ 2,575
(-34,97%)
8,13M
ABVEAbove Food Ingredients Inc
US$ 0,5338
(-34,42%)
1,66M
LGCLLucas GC Ltd
US$ 0,7511
(-33,53%)
2,48M
ADDColor Star Technology Company Ltd
US$ 4,19
(-31,87%)
205,78k
LESLLeslies Inc
US$ 2,445
(-30,34%)
24,55M
IDAIT Stamp Inc
US$ 0,364
(102,22%)
560,18M
ELABElevai Labs Inc
US$ 0,01255
(-21,07%)
325,82M
NVDANVIDIA Corporation
US$ 136,92
(0,66%)
190,3M
RGTIRigetti Computing Inc
US$ 2,195
(-20,18%)
126,72M
IMGCIMG Inc
US$ 1,615
(156,35%)
114,51M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen